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Abstract
THE EFFECT OF DENTAL PROBIOTIC USE ON THE INHIBITION OF
STREPTOCOCCUS MUTANS: A CLINICAL STUDY
DEGREE DATE: SEPTEMPER, 1ST 2020
HALAH THANOON, D.D.S.
COLLEGE OF DENTAL MEDICINE, NOVA SOUTHEASTERN UNIVERSITY
Thesis Directed by:
Evren Kilinc, D.D.S., Ph.D., M.P.H.
Sibel A. Antonson, D.D.S., Ph.D. M.B.A., Committee Member
Toshihisa Kawai, D.D.S., Ph.D., Committee Member

Brief Background: Streptococcus mutans (S.mutans) is the pioneering pathogenic bacteria
responsible for the initiation of dental caries. Controlling S.mutans activity using dental
probiotics may have an impact on caries incidence and oral health in general.
Objective: To evaluate the effects of commercially available dental probiotics (PRODental, Hyperbiotics Inc.) usage for 60 days in a row on the cariogenic bacterium S.mutans
in high caries risk patients with high or low S.mutans counts at baseline and 30 days after
the discontinuation of use.
Methodology: A total of 30 consenting adult patients with high caries risk (according to
NSU CAMBRA protocol) without any complex medical history or recent antibiotic usage
were recruited after IRB approval. Standardized oral hygiene instructions and oral hygiene
care kit were given to all patients after a periodontal cleaning. Baseline saliva sampling
was performed. Patients were given 60 day supply of dental probiotic tablets containing
live bacteria of S.salivarius K12, S.salivarius M18, L.reuteri, L.paracasei, and zinc (PRODental) following the manufacturer’s instructions (1tablet/day, before bed). After 30 days,
v

patients were recalled for saliva sampling, and they were instructed to continue using
probiotics. Upon completion of probiotic dose (60-days), the subjects were recalled for
saliva sampling. After 30 days of probiotics discontinuation, patients were recalled for the
last saliva collection. Saliva samples were collected at each time by chewing a paraffin
wax to stimulate salivation (1ml). The samples were then diluted to 100, 1000, and 10,000
times in phosphate-buffered saline. Resulting serially-diluted bacterial suspensions were
inoculated to a mitis-salivarius-bacitracin-potassium-tellurite agar plate and incubated in
an anaerobic jar at 37°C for 48h. S.mutans colonies observed on the agar plate were counted
using colony-forming units (CFU) per ml of stimulated saliva. The results were statistically
analyzed using Pairwise comparisons with Bonferroni adjustment of margins was used to
look for specific differences across time periods, and Poisson distribution was conducted
to account for the data measurement scale. Statistical significance was found at p<0.05.
Results: Across all cell counts of 100, 1000, 10000, and baseline, significant differences
were found across time (p < 0.05). S.mutans count decreased by %48.5 after 30 days and
by %83.9 after 60 days of probiotic usage. After 30 days of probiotic discontinuation.
S.mutans counts got increased by %14.4. The continued suppression of the S.mutans for
30 days was statistically significant (p < 0.05), it reduced by %69.5 from the baseline.
Compliance was 100%, with no adverse events.
Conclusion: The daily administration of dental probiotics for 60 days sufficiently
suppressed the level of oral S.mutans and suppression continued for 30 more days. Further
long-term research is needed to evaluate the sustainability of probiotics on the continued
suppression of this cariogenic bacterium.
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Chapter 1: Introduction
1.1 Probiotics
1.1.1 History
The first concept of probiotics was proposed by Elie Metchnikoff (Nobel awarded) in 1908
when he linked the long life and the decreasing number of chronic diseases of Bulgarian
peasants with their utilization of fermented milk products. However, this concept was not
clear since the bacteria within the milk were not identifiable except for ‘Bulgarian bacillus’,
and the culture was lost.1 The word “Probiotic” was first used in 1965 by Lilley and
Stillwell to describe substances secreted by one microorganism to stimulate the growth of
another. 2 In 2002, World Health Organization (WHO) believed in probiotics by publishing
guidelines to evaluate probiotics in food and they defined it as “live microorganisms which
when administered in adequate amounts confer a health benefit on the host.” 3
Conversely, Food and Drug Administration (FDA) approval is not required to sell probiotic
as dietary supplements as long as there are no health claims mentioned. If probiotic is going
to be marketed as drug to treat particular disease or disorder, it must be proven safe and
effective for its intended use through clinical trials and approval of FDA is needed before
it can be sold.4
The most common microorganisms used as probiotics are bacteria that belong to
Lactobacillus as L.rhamnous, Bifidobacterium as B.animalis, and Streptococcus as
streptococcus salivarius. Yeast also might be used as Saccharomyces boulardii. 5, 6
Probiotics are naturally present in oral microflora, gut microbiota, and in food like cheese,
fermented milk, and some vegetables.7 Alternatively, it can be synthetically found in
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different forms such as food (mostly dairy products), dietary supplements, or some
medications.
In the United States, 80% of manufactured yogurt had Lactobacillus and/or
Bifidobacterium strains added as probiotics. Dietary supplements, in pill or capsule form,
are another form of probiotics that produced by more than 80 different companies in the
United States only.8 The possible mode of administering probiotics is very different; for
instance, chewing gum, milk, cheese, yogurt, ice cream, drops, dust, lozenges, and
mouthwashes. Many probiotic supplements contain 1 to 10 billion CFU per dose, but some
contain up to 50 billion CFU or more. However, higher CFU counts do not necessarily
improve the product’s health effects.8

1.1.2 Mechanism of Action of Probiotics
Probiotic bacteria have several impacts on the host, which was entirely based on
gastrointestinal studies. Probiotics can influence the host immune system at both
systematic and mucosal level, and their effect can be observed on; intestinal luminal
environment, epithelial and mucosal barrier, and on numerous cell types involved in the
innate and adaptive immune responses, such as epithelial cells, dendritic cells,
monocytes/macrophages, B cells, and T cells. 9
In order to have an effect on the host, probiotic bacteria have to be large numbers to form
colonies. When those colonies come in touch with the epithelial cell, it will alter the cell
surface and make it relatively hydrophilic to permit nonspecific cell binding to probiotic
organisms. Thus, it creates thick surface-layer of protein that reduces the permeability of
epithelial cells to bacterial entropathogen and maintain barrier function. Besides, probiotics
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has the ability to obscure receptor binding sites and compete with pathogenic bacteria for
substrates available to prevent pathogens from binding, invading the host and downstream
their effect on host.10 Also, probiotic secretes bacteriocins, polypeptide antibiotic, that help
in preventing the growth of certain microorganisms and reduce their harmful byproducts.11
The indirect role of probiotics is on the host immune system. It secretes substances that
inhibit pathogen-induced cytokines resulting in a reduction of inflammation and tissue
damage. In addition, it stimulates nonspecific immunity and modulates humoral/cellular
immune that responds to adaptive immunity. 11, 12

1.1.3 Probiotic and General Health
Probiotics had different impacts on body systems based on their mechanism of action. In
gastrointestinal tract, probiotics can be used as an adjunctive therapy to treat
gastrointestinal infection, antibiotic-associated diarrheal diseases, colon cancer, food
allergies.13 It aids in treating many diseases like vaginosis and urinary tract infections by
creating a healthier environment within the vaginal flora.14 In addition, it used in
cholesterol reduction by reducing cholesterol absorption through the intestinal lumen.15 In
the liver, probiotics used to decrease total fatty acid content of the liver and reduce
endotoxemia associated with alcoholic liver.16 lately, scientists have been associated the
balanced diet and healthy microbiota with mental health as it improves cognitive function,
stress management, and decision-making.17

1.1.4 Probiotic and Oral Health
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According to Meurman, probiotics may have an interaction in dental plaque and its almost
identical mechanism of action as on general body systems. When administrating probiotics,
it may aid in dental biofilm formation that contain more friendly bacteria instead of harmful
cariogenic or periodontal bacteria, which are the cause of common oral diseases.18 It also
may compete with pathogenic bacteria for tooth attachment and available substances to
reduce their acidic byproducts and naturalize pH.18 Moreover, probiotic bacteria produce
chemicals (bacitracin) that help in growth inhibition of pathogenic bacteria like S.mutans,
Lactobacillus, A.actinomycetemcomitans, and P.gingivalis. For that, probiotics considered
one of the oral microflora modification therapy (preventive treatment). 19, 20
In periodontal disease, probiotics have shown to reduce all gingival and periodontal
indexes that related to gingivitis and periodontitis, as bleeding on probing, by initiating the
immune response to minimize the inflammatory response and secrete bacitracin that
inhibits the growth of certain bacteria. Numerous studies have been done to evaluate
probiotic effect on common periodontal diseases, and the relation is more believed than
dental caries. 21, 22
In candidal infection, candida Albicans is part of normal microflora and reasonable for
more than 70% of fungal infections in humans, and the role of probiotics is to maintain
homeostasis in the oral cavity and to decrease the growth of candida Albicans especially
in the elderly.23
In Halitosis, probiotic bacteria produce bacteriocins, which helps in reducing volatile sulfur
compounds that responsible for malodor and maintain oral microflora. 24

1.1.5 Probiotics and Dental Caries
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In dental caries, there are many studies which report the advantages of probiotics in
management of dental caries and its risk factors, especially regarding the bacteriological
count reduction, plaque pH control, and root caries lesions. However, only very few clinical
research studies addressed the effect of probiotics on the S.mutans and lactobacillus counts
in adult group.

25-27

Juneja et al. evaluated the effect of probiotic containing milk on S.mutans count among 40
children for 3 weeks. His results showed that there is statistically significant reduction in
salivary mutans streptococci counts immediately after consumption of probiotics.28
Moreover, Cildir et al. and Ashwin et al. assessed the effect of on S.mutans and
lactobacillus counts among adolescence patients. Their results revealed statistically
significant reduction in both bacterial counts. 29, 30
On the other hand, Caglar et al. evaluated the probiotics effect on S.mutans and
lactobacillus counts among young women with high S.mutans counts at the bassline for 10
days. The results were in agreement with the previous study that there is a significant
reduction in salivary bacterial counts. 31
Another study was done by Srivastava et al. to evaluate the effect of probiotic curd on
S.mutans and salivary pH on young adult for 7 days. A significant reduction was observed
in salivary pH and along with S.mutans count. 32
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1.2 Cariology
1.2.1 Caries Formation
Dental caries is a multifactorial disease which is complicated by host environmental and
bacterial factors. The initiation of caries acquired action of three primary factors (tooth,
dental plaque, and diet) that presented in a circular model in 1960s. 33 This model has been
supplemented with factors that modulate the actions of the primary factors to determine the
manifestation and clinical severity of caries (time, personal factors, and oral environmental
factors). 34
Teeth consist of a calcium phosphate mineral that demineralizes when the oral pH lowers
(> 5.5) due to acidic bacterial byproducts. As the pH recovers, dissolved calcium and
phosphate can reprecipitate on remaining mineral crystals (remineralization). In absence
or lack of remineralization, caries process will progress. 35
Dietary carbohydrates are necessary for the bacteria to produce the acids that initiate
demineralization. In general, dietary advice for caries prevention is depend on the drop in
pH lasts for approximately 30 minutes, frequency of intake is more important than the
quantity, and the stickiness of foods. 34
By clear understanding of how demineralization and remineralization occur, the role of
fluoride and salivary minerals to buffers the acids is understood. 34

1.2.2 Caries Risk Assessment
Risk assessment is a valuable tool for the prevention and management of dental caries. 36
The International Caries Detection and Assessment System (ICDAS) is an evidence-based
strategy that classifies the visual appearance of a lesion, characterization/monitoring of the
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lesion once detected, and finishes in diagnosis.37 Caries management by risk assessment
(CAMBRA) is a methodology of identifying the cause of disease through the assessment
of risk factors for each individual patient and then managing those risk factors through
behavioral, chemical and minimally invasive procedures. As this approach has been widely
used among dentists and professional organizations, it has now become a new standard of
care which should be incorporated into the dental hygiene process of care. 38 According to
CAMBRA, patients considered at high caries risk if they exhibit: (1) 2+ cavitated carious
lesions diagnosed during the current examination; (2) past root caries/large number of
exposed roots; (3) deep pits and fissures; (4) poor oral hygiene; (5) frequent sugar intake;
(6) inadequate or no systemic or topical fluoride exposure; (7) irregular dental visits; (8)
inadequate salivary flow; and (9) generalized white spots and/or incipient interproximal
radiolucencies. 38 The management of those patients is to control and downstream their risk
factors, which is highly dependent on the patient’s motivation and compliance.

1.2.3 Role of Cariogenic Bacteria on Caries Risk
Dental caries is a transmissible bacterial disease caused by cariogenic bacteria, streptococci
mutans and the lactobacillus, feeding on carbohydrate. The prevalence of streptococcus
mutans is associated with dental initiation, while lactobacilli flourish in a carious
environment and contribute to caries progression. 34
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1.2.4 Streptococcus Mutans
Streptococcus mutans (S.mutans) is a facultatively anaerobic, gram-positive coccus (round
bacterium) commonly found in the human oral cavity. It is a pioneering bacterium in dental
plaque due to its ability to attach to the tooth surface and ferment carbohydrate to produce
acid that demineralizes tooth structures.34 S.mutans had a direct correlation with dental
caries as it is highly associated with caries initiation. Therefore, controlling its activity
may have a significant impact on caries incidence. Thus, low counts of S.mutans in the oral
cavity are good predictors of low caries risk. S.mutans levels can be quantified from a
plaque or saliva sampling, and this procedure mostly requires a microbiological
laboratory.34 The methods include mitis salivarius agar, glucose-sucrose-potassiumtellurite-bacitracin agar, tryptone-yeast-cysteine-sucrose-bacitracin agar, and/or adding
certain salts and antibacterial agents to create special agar for S.mutans culturing and
enumeration. 39

1.2.5 Mitis-Salivarius Agar
Mitis-salivarius agar is a selective medium that developed for the isolation of S.mutans
from human dental plaque or saliva. It is the gold standard method to isolate S.mutans. 40
This agar can be modified by adding bacitracin, potassium tellurite, and by increasing the
sucrose concentration to increase the selectivity of the agar to S.mutans. Those agents
allowed the undiminished recovery of S.mutans with maximum inhibition of the balance
of the streptococcal flora normally encountered on this medium. 39
Bacitracin is a polypeptide antibiotic that inhibit growth of several bacteria other than
S.mutans. Potassium tellurite, K2TeO3, is an inorganic potassium-tellurium compound. It
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has been used as a selective growth medium in microbiology as it inhibits most gramnegative bacilli and most gram-positive bacteria. In a study by Srivastava et al., potassium
tellurite and bacitracin were added to mitis-salivarius agar to count S.mutans. This
combination was shown to be a reliable and consistent method to evaluate S.mutans.41
There are commercially available chair-side kits to count S.mutans as Caries Risk Test,
CariScreen, and Saliva-check mutans. They compose of mitis-salivarius agar with added
substances as well. However, agar media made in the laboratory showed higher sensitivity
than chair-side kits, as chairside kits may tend to grow other non-mutans organisms.42, 43
Krasse and Fure proposed that 105 mutans streptococci per milliliter of saliva could be
considered a high value in a person with only a few teeth and no restorations. However,
106 might not be an extremely high value in a person with many restorations. 44 Since all
the patients of this study are at high caries risk but not extremely high, < 5x105 has been
chosen as a limit value to evaluate high/low S.mutans number at the baseline.
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1.3 Probiotics and Long-Term Effects
There is insufficient evidence to recommend named bacteria or probiotic products for
specific conditions. Regarding the duration, the National Institute for Health and Care
Excellence

(NICE)

suggests

people

who

are

wishing to try probiotics are

encouraged to select one brand and take it at the recommended dose for at least four weeks
while monitoring the effect. However, no maximum duration was mentioned in all
products.
There are no published studies in the literature evaluating the S.mutans levels or any other
bacteria after the suspension of the probiotic usage. The main innovative part of this study
is assessing the extent of probiotic effect after its discontinuation.
This study is one of very few clinical studies that directed to adult group while most caries
related clinical researches are aiming to evaluate the inhibitory effect of probiotics on
children or adolescence. Additionally, this study was measuring the probiotic effect of two
months in row, which consider a relatively long period comparing to similar studies.
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1.4 Specific Aim and Hypothesis
1.4.1 The Aim:
The purpose of this study is to evaluate the possible inhibitory effects of commercially
available dental probiotics usage for 60 consecutive days on the cariogenic bacterium
S.mutans in the adult high caries risk patients with high or low S.mutans counts at baseline
and also to determine the lingering effects after one month after the discontinuation of
probiotic use.

1.4.2 Hypothesis:
1. Evaluate the level of cariogenic bacteria S.mutans inhibition when using dental
probiotic for 60 consecutive days.
2. Determine whether the inhibition effect on S.mutans incidence will continue at least
one month after the last dose of probiotics.
3. Observe and compare the inhibition effect of dental probiotics on S.mutans in
patients with higher baseline counts versus lower baseline counts.

1.4.3 Null Hypothesis:
1- There is no significant difference in S.mutans count and its cariogenic activity after
using dental probiotics for 60 consecutive days.
2- The inhibitory effect on S.mutans will not last for 30 days after discontinuation
probiotic.
3- There is no difference in the inhibition effect of probiotics on S.mutans in patients
with higher baseline counts versus lower baseline counts.
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1.5 Location of the Study:
-

Patient examination and data collection were done at Nova Southeastern University
College of Dental Medicine (NSU CDM) Post Graduate Operative Dentistry Clinic
and Research Clinic.

-

Agar plate preparation, saliva dilution, and bacterial culturing were done at NSU
CDM Research Lab I, Room 7391

-

Bacterial analysis and counting took place at NSU CDM Research Lab II, Room
7381

Nova Southeastern University
Health Professional Division
College of Dental Medicine
3200 South University Drive
Fort Lauderdale, Florida 33328-201
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2

Chapter 2: Materials and Methods

2.1 Patient Selection and Preparation
The study was approved by the Institutional Review Board (IRB#:2018-485-NSU) before
starting any of the clinical and laboratory procedures. All study samples (n=30) were
patients of record at NSU CDM, and they were evaluated for eligibility for the study
following the caries risk determination and acceptance of their treatment plans.
Inclusion criteria:
•

Adult population (18-99) years old.

•

High caries risk patients according to Caries Risk Management by Risk Assessment
Protocol (CAMBRA). 38

Exclusion criteria:
•

Pediatric or special needs patients.

•

Low caries risk patients.

•

Immune-suppressed patients.

•

Patients on long-term antibiotics.

•

Patients that are on long term antibacterial regimens (e.g. chlorhexidine).

•

Pregnant or nursing patients.

•

Edentulous patients.

•

Patients with very complex medical history or who will undergo in-patient
treatments/ hospitalizations.

•

Patients that use hydrogen peroxide, bleaching material, or coconut oil.

•

Patients with very high DMFT scores (>20).

22

2.1 Sample Size Calculation
This is an equivalence trial aimed to decide the sample size in this study.
The formula is as follows:
𝑍!"# + 𝑍!"% $
$
𝑁 =2𝑋 &
* 𝑋 𝑝 𝑋 (1 − 𝑝)
𝛿&
N=group size; p=the response rate of standard treatment group; zx= the standard
normal deviate for two-sided test; δ0= a clinically acceptable margin.
All parameters were assumed as follows: mean Streptococci Mutans in the treatment
group=4706; α=0.05; β=0.20; δ0=1000, p = 60.
From this we calculate a minimum sample size is 27-30 subjects.

2.2 Sample Selection and Standardization:
Subject selection, recruitment, evaluation, and all clinical/laboratory procedures
were done by a single operator (Dr. Thanoon) for standardization and calibration
purposes. In this study, the independent and dependent variables are described
below:
* Independent variables:
Probiotics PRO-Dental tablets (Hyperbiotics Inc.; Henderson, NV).
* Dependent variable:
Streptococcus Mutans count (higher or lower than 5x105/1ml of saliva).
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2.3 Clinical Procedures
Subjects that fit the inclusion/exclusion criteria were approached after they accepted
their Tx plans in PG Operative Clinic to be recruited to the study. The same operator
(Dr. Thanoon) recruited all patients. Patients who agreed to participate were given a
consent form to sign (Figure 23).
Patients were told that they would be enrolled after their periodontal cleaning is
completed and before their Fluoride treatments began. As an incentive, patients were
informed that they would receive 4 bacterial tests during this study = $100/each
($400) and 60 probiotic tablets were given free of charge to each patient = $45
(Total= $445/each patient).
Patients were informed that they would be dropped out of the study if they no longer
meet the criteria as taking antibiotics or antibacterial therapy, fail to show up to
scheduled appointments, and fail to follow the study directions e.g., stop using
probiotic for three consecutive days.

2.3.1 1st visit – Baseline-Initial procedures
Subjects that fit the inclusion/exclusion criteria and who agreed to participate and
signed the consent presented back after they received periodontal cleaning to be
enrolled in the study.
At the baseline visit, accepted patients had standard oral hygiene instructions and
oral hygiene kit containing a soft manual toothbrush (Oral B (The Procter and
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Gamble, Cincinnati, Ohio)), toothpaste (Colgate total (Colgate, New York City,
NY)) and dental floss (Oral-B Glide (The Procter and Gamble, Cincinnati, Ohio).
Medical history was checked. Then, clinical examination was performed to each
patient in order to count DMFT scores (decayed, missing, filled teeth according to
the modified dental caries index by Bodecker) and conifer their caries risk
assessment. All subjects presented having eaten at least an hour before saliva
collection. After the collection of the saliva samples, patient requested to start using
the dispensed probiotic tablets (60 tablets) starting with that night following the
verbal and written instruction (take 1 chewable tablet at bedtime, after brushing and
flossing your teeth, please refrain from eating and drinking until the next morning).
This protocol is to be continued for 60 consecutive days, but patients need to be
present for the follow up after 30 days. Patients were given a diary log sheet as a
reminder and which they were asked to mark every time they used probiotic. They
were requested to bring the log sheet to their upcoming appointments (Figure 1).

25

Figure 1. Oral hygiene kit

Scanned with CamScanner
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2.3.2 1st visit – Baseline- Saliva collection
Patients were requested to chew the paraffin wax for about 3-4 minutes to stimulate
salivation. Then, they were asked to spit out saliva (1ml) in a sterile container.
Saliva samples were identified by giving a code number which was written on the
collecting bottle, using a waterproof pen. The collected salivary sample was then
be transported to the laboratory (Research Lab I, Room 7391, NSU CDM)
immediately and processed within 6 hours (Figure 2).

Figure 2. Saliva collection
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2.3.3. 1st visit – Baseline – Probiotic Distribution
The patients were blinded to the probiotic brand and were handed out capsules in
generic bottles with customized labels. The probiotic tablets used were PRO-Dental
Probiotic (Company name (Hyperbiotics whatever); full addressHenderson, NV).
Patients were informed that these pribiotics are commercially available, they are
made in the USA in a certified Good Manufacturing Practice (GMP) facility. They
are also lactose-free, vegetarian, non-GMO, yeast free, no lactose, no soy, no iron,
no gluten, no wheat, no nuts, no preservatives Contents of 1 tablet include Zinc
2mg and Proprietary Probiotics Blend of 3 billion CFU (S. salivarius K
12, S.Salivarius M 18, L. reuteri, L paracasei). (Figure 3). (Figure 4). 2mg and
Proprietary Probiotics Blend of 3 billion CFU (S. salivarius K 12, S.Salivarius M
18, L. reuteri, L paracasei). (Figure 3). (Figure 4).
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Figure 3. PRO-Dental probiotics
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Figure 4. Research bottle
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2.3.2 2nd visit (30 days after using probiotics): (change number)
After 30 consecutive days of probiotic usage, patients reported back to NSU CDM
PG Operative Dentistry Clinic/Research Clinic having eaten at least an hour where
saliva collection was done for microbiological analysis. Medical history was
updated. Patients were reminded to continue to take the probiotic tablets, oral
hygiene instructions were reviewed verbally, and log sheet was checked. Patients
were asked if they demonstrated any symptoms or any side effects throughout this
study period.
Saliva samples were collected and analyzed using the same methods of initial visit.

2.3.3 3rd visit (60 days after using probiotics):
Patients reported back to NSU PG Operative Dentistry Clinic/Research Clinic
having eaten at least an hour where saliva collection was done for microbiological
analysis. Medical history was updated. Patients were asked to discontinue the
probiotics, oral hygiene instructions were reviewed verbally, and log sheet was
checked. Patients were asked if they demonstrated any symptoms or any side effects
throughout this study period. Saliva samples were collected and analyzed using the
same methods of initial visit.
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2.3.4 4th visit – final visit (30 days after discontinuation of using
probiotics):
Patients reported back to NSU PG Operative Dentistry Clinic/Research Clinic where
saliva collection was done for microbiological analysis for the last time. Medical
history was updated. Oral hygiene instructions and home care techniques were
reviewed to make sure that you are maintaining good oral hygiene. Clinical
examination was performed and, DMFT was recounted. Since the patients at high
caries risk, they were told to resume their preventive dentistry treatments such as
Fluoride varnish, high Fluoride toothpaste, MI paste. Patient’s compliance check was
performed. Patients received 60 days’ supply of probiotic tablets at the beginning of
the study. To assess compliance, the number of remaining tablets returned by each
patient was counted to confirm the missed consumption of probiotics. All study
samples (n=30) were able to show up in baseline and recall appointments. Patients
demonstrated no symptoms or any side effects throughout study period.

2.4 Laboratory Procedures
2.4.1 Mitis-salivarius Bacitracin Potassium-tellurite agar Preparation
Mitis salivarius (Sigma Aldrich (St. Louis, MO)) media was prepared as the
following:
-

Suspend 9.07 grams of mitis- salivarius in 100 ml of distilled water (Figure 5).

-

Heat to boiling to dissolve the medium completely using thermal mixer (VWR,
Radnor, PA) for 10 minutes (Figure 6).
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-

Dispense and sterilize by autoclaving at 15 lbs. pressure (121°C) for 30 minutes
(Tuttnauer, NY) (Figure 7).

-

Cool to 50-55°C and transfer it to biosafety cabinet in sterile conditions to
eliminate contamination (Labconco, VWR (Radnor, PA)) (Figure 8).

-

In the cabinet, mix 0.01 gm of potassium tellurite (Sigma Aldrich (St. Louis, MO))
in 1 ml of distilled water (Figure 9).

-

In the cabinet, mix 0.002 gm of bacitracin (Sigma Aldrich (St. Louis, MO)) in 1
ml distilled water (Figure 10).

-

After cooling the agar media, add 100 µl of potassium tellurite and 150 µl of
bacitracin in a sterile environment.

-

Do not reheat the medium after adding potassium tellurite and bacitracin

-

Mix well and pour into sterile petri dishes 15mm (VWR (Radnor, PA)) (Figure
11)

-

Wait till it cool down completely before incubation

-

if not used in the same day, wrap it well and keep it in the refrigerator at 2-8 °C.
•

Quality Control
Petri plates were firm and dark blue colored clear to slightly opalescent gel.
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Figure 5. Mitis salivarius agar
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Figure 7. Thermal mixer

Figure 6. Automatic autoclave
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Figure 9. Bacitracin

Figure 8. Potassium tellurite
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Figure 10. Biosafety cabinet

Figure 11. Petri dish
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2.4.2 Saliva Dilution and Incubation
Saliva dilution is an essential step in S.mutans incubation since the later presented
in human saliva in large numbers. Thus, in order to get countable numbers of
S.mutans, saliva needs to be diluted. In this study, saliva was diluted to 100, 1000
and 10,000 times in phosphate buffered saline (PBS) 7.4 pH (Thermo Fisher
scientific, Weston, FL) (Figure 12).
Saliva sample was vortexed using vortex mixer (VWR, Radnor, PA) for 15 sec. and
transferred to biosafety cabinet.
Figure 12. Phosphate buffered saline
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•

Saliva was diluted as following:

- 10 µl of saliva was added to 990 µl of PBS to get 100-time diluted saliva.
- 100-time diluted saliva was added to 900 µl of PBS to get 1000-time diluted saliva.
- 1000-time diluted saliva was added to 900 µl of PBS to get 10000-time diluted saliva.

•

Saliva incubation

Serially diluted bacterial suspensions were inoculated to mitis-salivariusbacitracin-potassium-tellurite agar plates (50 ml each). In order to control sterility
of agar plates, 50 ml of clear PBS was plated in each incubation. Incubation of all
agar was carried out in an anaerobic jar at 37°C for 48 h (VWR (Radnor, PA))
(Figure 13). After 48h, Petri dishes were transferred to laminar flow cabinet (Air
Science, Fort Myers, FL) for S.mutans colonies observing and counting using
colony-forming units (CFUs) at different dilution factors (Figure 14,15,16,17). PBS
plate was clear (no colonies observed) in every incubation (Figure 18).

Counted S.mutans colonies were calculated based on the following equation:
No. of colonies x dilution factor x 20 = colony-forming unit (CFU)/ 1ml of saliva
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Figure 14. VWR incubator

Figure 13. Laminar flow cabinet
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Figure 16. S.mutans colonies observed on 1000-time diluted saliva

Figure 15. S.mutans colonies observed on 100-time diluted saliva
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Figure 17. S.mutans colonies observed on 10000-time diluted saliva

Figure 18. PBS plate - no colonies
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2.5 Statistical Analysis:
Poisson distribution was used to account for the data measurement scale. Pairwise
comparisons of margins with a Bonferroni adjustment were used to look for specific
differences across time periods. A significance level of 0.05 was used for all tests. Pairwise
correlations between DMFT and counts 100, 1000, 10000, and baseline were conducted.
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Chapter 3: Results
Four mixed generalized liner models were conducted to observe the differences in probiotic
count in attenuated saliva at 100, 1000, 10000 dilution factors, and baseline over time. The
fixed effects were time (baseline, 2nd visit, 3rd, 4th visit) and sex (female, male. The
random effect was the subject. Poisson distribution was used also to account for the data
measurement scale. The results show that there is a significant reduction in S.mutans counts
after using probiotics for 60 consecutive days and even after its suspension for 30 days (p
< 0.05).
The reduction was observed at all saliva dilution factors 100, 1000, and 10000. However,
there was no distinction between male and female patients. Considering the average
numbers, the highest difference in S.mutans counts were found between baseline
(mean=881440) and third visit (60 days after using probiotics) (mean=244817) (Table 1).
Pairwise comparisons of margins with a Bonferroni adjustment was used to look for
specific differences across time periods, baseline (before using probiotics), 2nd visit (30
days of using probiotics), 3rd visit (60 days of using probiotics), and 4th visit (30 days after
stop using probiotics). Statistically significant difference were found between baseline and
2nd visit, baseline and 3rd visit, and 2nd and 3rd visit (p < 0.0001). However, there is no
statistically difference between 3rd and 4th visit. Moreover, the great difference between
baseline and 4th visit (p < 0.0001) proof that the effect of probiotic on S.mutans counts
would last at least for 30 days after its discontinuation (Table 2).
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Table 1. Descriptive statistics for time and gender
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Table 2. Pairwise comparisons by time
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Margin plots were created to show the reduction in S.mutans numbers (the mean values
were considered) at different dilution factors and the average of all factors. Reflecting the
average values, S.mutans counts dropped by %48.5 from baseline to 2nd visit (30 days of
using probiotics) and continued to decrease by %35.4 from 2nd to 3rd visit (60 days of using
probiotics). Accordingly, the total reduction of S.mutans count after 60 days of probiotic
usage is %83.9. However, it got slightly increased by %14.4 from 3rd to 4th visit (30 days
after using probiotics), but still significantly reduced compared to baseline counts (%69.5)
(P<0.05) (Figure 19-21) (Table 3).

As it was determined whether S.mutans counts were high or low at baseline visit based on
value of (5x105/1ml of saliva), %77 of patients presented with high S.mutans counts at the
baseline. However, after 30 days of probiotic usage, only %20 of patients had high
S.mutans counts. After 60 days of using probiotics and 30 days after probiotics
discontinuation, all patients presented with low S.mutans counts.

In addition, results illustrate that patients presented with high DMFT counts demonstrated
higher S.mutans counts at the baseline. Still, no statistical difference found between
gender. After 60 days of probiotic usage, patients presented with high DMFT scores
and S.mutans count at the baseline showed a significant reduction in the S.mutans counts
while DMFT scores were still the same.

Patients were able to present in all appointments (Compliance rate %100). Probiotic tablet
consumption was self-reported and confirmed by counting the remaining tablets in the

47

retuned bottles, and it exceeded 90% over the 60 days, indicating perfect compliance. No
adverse effect was detected or reported.
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Figure 19. Margin plot for time and gender for 100
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Figure 20. Margin plot for time and gender for 1000
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Figure 21. Margin plot for time and gender for 10000
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Figure 22. Margin plot for time and gender for average
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Table 3. Percent Change
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Chapter 4: Discussion
The first null hypothesis that there is no significant difference in S. mutans count after using
dental probiotics (PRO-Dental) for 60 consecutive days must be rejected. In the present
study, S mutans count decreased by %83.9 after 60 days of probiotic usage. This study has
no control group, yet findings were corroborated by many previous studies that evaluated
S.mutans level in saliva after oral probiotic therapy in both adults and children, using
different probiotic strains.
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Additionally, this study was directed to the adult group

while most of caries related clinical research aimed to evaluate the inhibitory effect of
probiotics on children or adolescents. This clinical study evaluated the S.mutans counts
after 60 days of probiotics usage, which consider to be relatively long period comparing to
similar studies.

Conversely, some studies contradicted the findings of this study, as they reported no
changes in salivary S.mutans levels after probiotic administration.45,
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Gizani et al.

evaluated the effect of 2 strains of Lactobacillus reuteri on salivary S.mutans, L.bacillus,
and white spot lesions among orthodontic patients after debonding. In their results, there
was a significant reduction in L.bacillus counts while no noticeable changes in the S.mutans
counts were unveiled. This conclusion opposed several studies, including the present
study.46

This study is unique as it evaluated the prolonged effect of probiotic on the S.mutans levels
after 30 days of its discontinuation. In the literature, there are no published studies
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evaluated that prolonged effect of any probiotic strains on S.mutans or any other bacteria.
Furthermore, no studies or dietary products recommended the duration of probiotic usage.
The study finding revealed that S.mutans level got increased by %14.4 from 3rd (60 days
of probiotic usage) to 4th visit (30 days after probiotic discontinuation), although still
significantly reduced compared to baseline counts (%69.5) (P<0.05). Thus, the second null
hypothesis that the inhibitory effect on S.mutans will not last 30 days after probiotic
discontinuation was rejected as well.

Study findings indicate that from baseline to 1st visit (30 days of probiotic usage), patients
presented with high S.mutans counts at the baseline showed higher reduction in bacterial
counts comparing to low S.mutans counts. However, in the following appointments, there
was no difference in the inhibition effect of probiotics on S.mutans in patients with higher
vs. lower baseline counts. As only high caries risk patients were included in the study, it
can be concluded that patients with low S.mutans counts still can be at high caries risk.
No studies have been reported the effect of (PRO-Dental) probiotic on S.mutans before the
present study. Based on the results and patients’ feedback, it has been shown that (PRODental) probiotics can be used safely and that tablets are an easy and acceptable vehicle
for probiotic administration, as demonstrated by the high compliance.
Mitis-salivarius agar with added bacitracin and potassium tellurite that increased selectivity
of the media toward S.mutans showed to be very consistent and reliable method since each
saliva sample was diluted to three dilution factors and similar colonies counts were
observed.
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There were unavoidable limitations. In the study, samples were recruited conveniently
since all patients were NSU-CDM patients. Additionally, one type of probiotics (PRODental) that contained 4 different bacterial strains was used and the effect on S.mutans
could not be related to certain strain. Another limitation is that only S.mutans colonies
were evaluated in this study. However, L.bacillus is related to caries as well by its role in
caries progression. Thus, further studies are needed to evaluate the immediate and
prolonged effect of probiotic on L.bacillus. Moreover, the results suggest the correlation
between probiotics and S.mutans counts and dental caries, not causation.
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Chapter 5: Conclusion
According to the results of this study, the daily administration of dental probiotics for two
months sufficiently suppressed the level of oral S.mutans. However, further long-term
research is needed to evaluate the sustainability of probiotics on the continued suppression
of this cariogenic bacterium. It is also important to clarify that probiotics are an additional
tool, not a substitute for the classic oral hygiene methods.
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Chapter 7: Appendix
Figure 23: Consent form
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